Photostabilized and / or viscosity-stabilized atropine-containing aqueous pharmaceutical composition
TW202639124APending Publication Date: 2026-10-01SANTEN PHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- TW114147697
- Authority / Receiving Office
- TW · TW
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-03-26
- Filing Date
- 2025-12-05
- Publication Date
- 2026-10-01
Smart Images

Figure TWG2TA001078685_001 
Figure TWG2TA001078685_002 
Figure TWG2TA001078685_003
Abstract
This invention provides an ophthalmic pharmaceutical preparation and its light stabilization method and / or viscosity reduction prevention method. The ophthalmic pharmaceutical preparation is an aqueous pharmaceutical composition contained in a direct package that is visible internally and blocks light of a specific wavelength. The aqueous pharmaceutical composition contains 0.001 to 0.1% (w / v) of atropine or its salt and a thickener, and achieves light stabilization and / or prevents viscosity reduction. The thickener is at least one selected from the group consisting of hydroxyethyl cellulose (HEC), hydroxypropyl methylcellulose (HPMC), and sodium carboxymethyl cellulose (CMCNa). The specific wavelength is (i) 210 to 380 nm when the thickener is hydroxyethyl cellulose and / or hydroxypropyl methylcellulose, or (ii) 210 to 410 nm when the thickener contains sodium carboxymethyl cellulose.
Need to check novelty before this filing date? Find Prior Art
